Analyst Conference Summaries

Biotechnology Investor Aids

Vascular Biogenics
VBLT

conference date: August 16, 2018 @ 5:30 AM Pacific Time

VBL Therapeutics (VBLT) Announces Top-Line Results from Pivotal Phase 3 GLOBE Study in Glioblastoma

I first bought Vascular Biogenics in June 2016. The stock price plunged on March 8, 2018 when the glioblastoma trial produced negative results.

2018
Vascular Biogenics
(VBLT)
 
March 15, 2018
May 17, 2018
August 16, 2018
 

Vascular Biogenics (VBLT) is a clinical-stage biotechnology company specializing in cancer therapies. It is also known as VBL Therapeutics.

Vascular Biogenics (VBLT) web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN
 
 

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2018 William P. Meyers